Determination of Regulatory Review Period for Purposes of Patent Extension; RECOTHROM, 38658-38659 [E9-18528]
Download as PDF
38658
Federal Register / Vol. 74, No. 148 / Tuesday, August 4, 2009 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
materially false laboratory entries and
altered information from a radiology
display report, which were critical
factors in determining whether the
individual was eligible to participate in
the clinical study. He also admitted to
knowingly and willfully
misrepresenting the results of a blood
chemistry analysis related to the
participation of a study subject who
would not otherwise have met the
criteria for that study. The subject was
administered chemotherapeutic drugs in
connection with the clinical study and
died as a result thereof. Mr. Kornak’s
failure to perceive a substantial and
unjustifiable risk that death would
occur when he knowingly and willingly
made and used such false documents
constituted a gross deviation from the
standard of care that a reasonable
person would observe in the situation.
Mr. Kornak further admitted to
knowingly and willfully using interstate
mail for the purpose of executing the
aforesaid scheme and artifice to defraud,
deprive, and obtain money and
property.
As a result of these convictions, FDA
sent Mr. Kornak by certified mail on
May 4, 2009, a notice proposing to
permanently debar him from providing
services in any capacity to a person that
has an approved or pending drug
product application. The proposal was
based on a finding, under section
306(a)(2)(A) and (a)(2)(B) of the act, that
Mr. Kornak was convicted of felonies
under Federal law for conduct relating
to the development or approval of a
drug product, and for conduct otherwise
relating to the regulation of a drug
product under the act. The proposal also
offered Mr. Kornak an opportunity to
request a hearing, providing him 30
days from the date of receipt of the letter
in which to file the request, and advised
him that failure to request a hearing
constituted a waiver of the opportunity
for a hearing and of any contentions
concerning this action. Mr. Kornak did
not request a hearing and has, therefore,
waived his opportunity for a hearing
and any contentions concerning his
debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Acting Director, Office
of Enforcement, Office of Regulatory
Affairs, under section 306(a)(2)(A) and
(a)(2)(B) of the act, and under authority
delegated to the Acting Director (Staff
Manual Guide 1410.35), finds that Mr.
Kornak has been convicted of felonies
under Federal law for conduct relating
to the development of approval of a
drug product and conduct otherwise
relating to the regulation of a drug
product under the act.
VerDate Nov<24>2008
16:07 Aug 03, 2009
Jkt 217001
As a result of the foregoing finding,
Mr. Kornak is permanently debarred
from providing services in any capacity
to a person with an approved or
pending drug product application under
sections 505, 512, or 802 of the act (21
U.S.C. 355, 360b, or 382), or under
section 351 of the Public Health Service
Act (42 U.S.C. 262), effective (see DATES)
(see sections 306(c)(1)(B) and
(c)(2)(A)(ii) and 201(dd) of the act (21
U.S.C. 335a(c)(1)(B) and (c)(2)(A)(ii),
and 321(dd)). Any person with an
approved or pending drug product
application who knowingly employs or
retains Mr. Kornak as a consultant or
contractor, or otherwise uses in any
capacity the services of Mr. Kornak
during Mr. Kornak’s permanent
debarment, will be subject to civil
money penalties (section 307(a)(6) of the
act (21 U.S.C. 335b(a)(6))). If Mr.
Kornak, during his period of debarment,
provides services in any capacity to a
person with an approved or pending
drug product application, he will be
subject to civil money penalties (section
307(a)(7) of the act). In addition, FDA
will not accept or review any
abbreviated new drug applications
submitted by or with the assistance of
Mr. Kornak during his period of
debarment (section 306(c)(1)(B) of the
act).
Any application by Mr. Kornak for
special termination of debarment under
section 306(d)(4) of the act should be
identified with Docket No. 2007–N–
0501 and sent to the Division of Dockets
Management (see ADDRESSES). All such
submissions are to be filed in four
copies. The public availability of
information in these submissions is
governed by 21 CFR 10.20(j).
Publicly available submissions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: July 20, 2009.
Alyson L. Saben,
Acting Director, Office of Enforcement, Office
of Regulatory Affairs.
[FR Doc. E9–18619 Filed 8–3–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–E–0258; FDA–2008–
E–0260; and FDA–2008–E–0261]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; RECOTHROM
AGENCY:
Food and Drug Administration,
HHS.
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
RECOTHROM and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of three applications to the
Director of Patents and Trademarks,
Department of Commerce, for the
extension of patents which claim that
human biological product.
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human
biological products, the testing phase
begins when the exemption to permit
the clinical investigations of the human
biological product becomes effective
and runs until the approval phase
begins. The approval phase starts with
the initial submission of an application
to market the human biological product
and continues until FDA grants
permission to market the human
biological product. Although only a
portion of a regulatory review period
may count toward the actual amount of
extension that the Director of Patents
and Trademarks may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human biological product will include
E:\FR\FM\04AUN1.SGM
04AUN1
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 74, No. 148 / Tuesday, August 4, 2009 / Notices
all of the testing phase and approval
phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing
the human biological product
RECOTHROM (Thrombin, topical
(Recombinant)). RECOTHROM is
indicated as an aid to hemostasis
whenever oozing blood and minor
bleeding from capillaries and small
venules is accessible and control of
bleeding by standard surgical
techniques is ineffective or impractical.
Subsequent to this approval, the Patent
and Trademark Office received patent
term restoration applications for
RECOTHROM (U.S. Patent Nos.
5,476,777, 5,502,034, and 5,527,692)
from ZymoGenetics, Inc., and the Patent
and Trademark Office requested FDA’s
assistance in determining the patents’
eligibilities for patent term restoration.
In a letter dated February 26, 2009, FDA
advised the Patent and Trademark
Office that this human biological
product had undergone a regulatory
review period and that the approval of
RECOTHROM represented the first
permitted commercial marketing or use
of the product. Thereafter, the Patent
and Trademark Office requested that
FDA determine the product’s regulatory
review period.
FDA has determined that the
applicable regulatory review period for
RECOTHROM is 1,511 days. Of this
time, 1,115 days occurred during the
testing phase of the regulatory review
period, while 396 days occurred during
the approval phase. These periods of
time were derived from the following
dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355(i)) became effective: November 30,
2003. FDA has verified the applicant’s
claims that the date the investigational
new drug application became effective
was on November 30, 2003.
2. The date the application was
initially submitted with respect to the
human biological product under section
351 of the Public Health Service Act (42
U.S.C. 262): December 18, 2006. FDA
has verified the applicant’s claims that
the biologics license application (BLA)
for RECOTHROM (BLA 125248/0) was
initially submitted on December 18,
2006.
3. The date the application was
approved: January 17, 2008. FDA has
verified the applicant’s claims that BLA
125248/0 was approved on January 17,
2008.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the U.S. Patent and
VerDate Nov<24>2008
16:07 Aug 03, 2009
Jkt 217001
Trademark Office applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 952 days of patent
term extension.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see ADDRESSES) written or
electronic comments and ask for a
redetermination by October 5, 2009.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
February 1, 2010. To meet its burden,
the petition must contain sufficient facts
to merit an FDA investigation. (See H.
Rept. 857, part 1, 98th Cong., 2d sess.,
pp. 41–42, 1984.) Petitions should be in
the format specified in 21 CFR 10.30.
Comments and petitions should be
submitted to the Division of Dockets
Management. Three copies of any
mailed information are to be submitted,
except that individuals may submit one
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document.
Comments and petitions may be seen
in the Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
Dated: June 8, 2009.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. E9–18528 Filed 8–3–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–E–0551]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; XIENCE V EECSS
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for XIENCE
V EECSS and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of an
application to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of a patent
which claims that medical device.
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
38659
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For medical devices,
the testing phase begins with a clinical
investigation of the device and runs
until the approval phase begins. The
approval phase starts with the initial
submission of an application to market
the device and continues until
permission to market the device is
granted. Although only a portion of a
regulatory review period may count
toward the actual amount of extension
that the Director of Patents and
Trademarks may award (half the testing
phase must be subtracted as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a medical device will include
all of the testing phase and approval
phase as specified in 35 U.S.C.
156(g)(3)(B).
FDA recently approved for marketing
the medical device, XIENCE V EECSS.
XIENCE V EECSS is indicated for
improving coronary luminal diameter in
patients with symptomatic heart disease
due to de novo native coronary artery
lesions (length = 28 millimeters (mm))
with reference vessel diameters of 2.5
mm to 4.25 mm. Subsequent to this
approval, the Patent and Trademark
Office received a patent term restoration
application for XIENCE V EECSS (U.S.
Patent No. 5,451,233) from Abbott
Cardiovascular Systems, Inc., and the
Patent and Trademark Office requested
E:\FR\FM\04AUN1.SGM
04AUN1
Agencies
[Federal Register Volume 74, Number 148 (Tuesday, August 4, 2009)]
[Notices]
[Pages 38658-38659]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-18528]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-E-0258; FDA-2008-E-0260; and FDA-2008-E-0261]
Determination of Regulatory Review Period for Purposes of Patent
Extension; RECOTHROM
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for RECOTHROM and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of three applications to the Director of
Patents and Trademarks, Department of Commerce, for the extension of
patents which claim that human biological product.
ADDRESSES: Submit written comments and petitions to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of
Regulatory Policy, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 51, rm. 6222, Silver Spring, MD 20993-0002, 301-796-3602.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Public Law 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human biological products, the
testing phase begins when the exemption to permit the clinical
investigations of the human biological product becomes effective and
runs until the approval phase begins. The approval phase starts with
the initial submission of an application to market the human biological
product and continues until FDA grants permission to market the human
biological product. Although only a portion of a regulatory review
period may count toward the actual amount of extension that the
Director of Patents and Trademarks may award (for example, half the
testing phase must be subtracted as well as any time that may have
occurred before the patent was issued), FDA's determination of the
length of a regulatory review period for a human biological product
will include
[[Page 38659]]
all of the testing phase and approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing the human biological product
RECOTHROM (Thrombin, topical (Recombinant)). RECOTHROM is indicated as
an aid to hemostasis whenever oozing blood and minor bleeding from
capillaries and small venules is accessible and control of bleeding by
standard surgical techniques is ineffective or impractical. Subsequent
to this approval, the Patent and Trademark Office received patent term
restoration applications for RECOTHROM (U.S. Patent Nos. 5,476,777,
5,502,034, and 5,527,692) from ZymoGenetics, Inc., and the Patent and
Trademark Office requested FDA's assistance in determining the patents'
eligibilities for patent term restoration. In a letter dated February
26, 2009, FDA advised the Patent and Trademark Office that this human
biological product had undergone a regulatory review period and that
the approval of RECOTHROM represented the first permitted commercial
marketing or use of the product. Thereafter, the Patent and Trademark
Office requested that FDA determine the product's regulatory review
period.
FDA has determined that the applicable regulatory review period for
RECOTHROM is 1,511 days. Of this time, 1,115 days occurred during the
testing phase of the regulatory review period, while 396 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective:
November 30, 2003. FDA has verified the applicant's claims that the
date the investigational new drug application became effective was on
November 30, 2003.
2. The date the application was initially submitted with respect to
the human biological product under section 351 of the Public Health
Service Act (42 U.S.C. 262): December 18, 2006. FDA has verified the
applicant's claims that the biologics license application (BLA) for
RECOTHROM (BLA 125248/0) was initially submitted on December 18, 2006.
3. The date the application was approved: January 17, 2008. FDA has
verified the applicant's claims that BLA 125248/0 was approved on
January 17, 2008.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 952 days of
patent term extension.
Anyone with knowledge that any of the dates as published are
incorrect may submit to the Division of Dockets Management (see
ADDRESSES) written or electronic comments and ask for a redetermination
by October 5, 2009. Furthermore, any interested person may petition FDA
for a determination regarding whether the applicant for extension acted
with due diligence during the regulatory review period by February 1,
2010. To meet its burden, the petition must contain sufficient facts to
merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d
sess., pp. 41-42, 1984.) Petitions should be in the format specified in
21 CFR 10.30.
Comments and petitions should be submitted to the Division of
Dockets Management. Three copies of any mailed information are to be
submitted, except that individuals may submit one copy. Comments are to
be identified with the docket number found in brackets in the heading
of this document.
Comments and petitions may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: June 8, 2009.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. E9-18528 Filed 8-3-09; 8:45 am]
BILLING CODE 4160-01-S